US5811524A
(en)
*
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
FR2758331B1
(fr)
*
|
1997-01-14 |
1999-03-05 |
Univ Bourgogne |
Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US7033589B1
(en)
*
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
WO1999012553A1
(en)
*
|
1997-09-08 |
1999-03-18 |
Idec Pharmaceuticals Corporation |
Methods for producing human antibodies in scid mice using dendritic cells
|
EP2261229A3
(en)
*
|
1998-04-20 |
2011-03-23 |
GlycArt Biotechnology AG |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
US6900299B1
(en)
*
|
1999-03-11 |
2005-05-31 |
University Of South Florida |
Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
|
AR030019A1
(es)
*
|
1999-05-18 |
2003-08-13 |
Smithkline Beecham Corp |
Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
|
GB9918788D0
(en)
*
|
1999-08-10 |
1999-10-13 |
Leuven K U Res & Dev |
Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
|
US6680209B1
(en)
*
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
ATE474854T1
(de)
*
|
2000-01-27 |
2010-08-15 |
Medimmune Llc |
Rsv neutralisierende antikörper mit sehr hohen affinität
|
AU2002219944B2
(en)
*
|
2000-11-28 |
2008-02-21 |
Medimmune, Llc |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
WO2001056602A2
(en)
|
2000-02-02 |
2001-08-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cd40 ligand adjuvant for respiratory syncytial virus
|
ES2390761T3
(es)
*
|
2000-03-01 |
2012-11-16 |
Medimmune, Llc |
Anticuerpos recombinantes de alta potencia y método para producción de los mismos
|
WO2001082965A1
(en)
*
|
2000-05-03 |
2001-11-08 |
Medimmune, Inc. |
Combination therapy of respiratory diseases using antibodies
|
US6855493B2
(en)
*
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US6818216B2
(en)
*
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
EP1370292A1
(en)
|
2001-01-31 |
2003-12-17 |
Idec Pharmaceuticals Corporation |
Use of cd23 antagonists for the treatment of neoplastic disorders
|
CN1509328A
(zh)
*
|
2001-03-23 |
2004-06-30 |
|
Opg配体调节免疫应答的作用
|
AU2002307037B2
(en)
*
|
2001-04-02 |
2008-08-07 |
Biogen Idec Inc. |
Recombinant antibodies coexpressed with GnTIII
|
WO2002102303A2
(en)
|
2001-05-01 |
2002-12-27 |
Medimmune, Inc. |
Crystals and structure of synagis fab
|
AU2002315534B2
(en)
*
|
2001-07-10 |
2008-05-22 |
Biogen Idec Inc. |
Inhibition of apoptosis process and improvement of cell performance
|
HUP0700103A3
(en)
|
2001-08-03 |
2012-09-28 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
US7306919B1
(en)
*
|
2001-10-31 |
2007-12-11 |
Thornthwaite Jerry T |
Antigen-antibody cancer recognition system
|
JP2005522996A
(ja)
*
|
2001-11-02 |
2005-08-04 |
セントカー・インコーポレーテツド |
Rsvタンパク質、抗体、組成物、方法および使用
|
CA2482333A1
(en)
*
|
2002-02-11 |
2003-08-21 |
Alexion Pharmaceuticals, Inc. |
Human antibodies for therapy against vaccinia or smallpox
|
CA2476232A1
(en)
*
|
2002-02-11 |
2003-08-21 |
Alexion Pharmaceuticals, Inc. |
Production of human antibodies in immunodeficient, non-human, mammalian hosts
|
AU2003220805A1
(en)
*
|
2002-03-28 |
2003-10-13 |
Yamanouchi Pharmaceutical Co., Ltd. |
Antiopoietin-related growth factor
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
WO2004001035A1
(en)
*
|
2002-06-21 |
2003-12-31 |
Centocor, Inc. |
Method for generating monoclonal antibodies
|
JP2005533861A
(ja)
*
|
2002-07-25 |
2005-11-10 |
メデュームン,インコーポレーテッド |
抗RSV、抗hMPV、および抗PIV抗体を使用するRSV、hMPV、およびPIVの治療法と予防法
|
KR100604038B1
(ko)
*
|
2002-08-02 |
2006-07-24 |
주식회사유한양행 |
항체 중쇄 발현벡터
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
CN1849337A
(zh)
*
|
2003-01-27 |
2006-10-18 |
比奥根艾迪克Ma公司 |
利用igsf9和liv-1的、用于治疗癌症的组合物及方法
|
US20040208869A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
PL378582A1
(pl)
|
2003-03-19 |
2006-05-02 |
Biogen Idec Ma Inc. |
Białko wiążące receptor Nogo
|
EP1614693A4
(en)
*
|
2003-03-31 |
2006-07-19 |
Kirin Brewery |
PURIFICATION OF A HUMAN MONOCLONAL ANTIBODY AND A HUMAN POLYCLONAL ANTIBODY
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US7070786B2
(en)
*
|
2003-06-06 |
2006-07-04 |
Centocor, Inc. |
RSV proteins, antibodies, compositions, methods and uses
|
CA2530172A1
(en)
|
2003-06-27 |
2005-02-10 |
Abgenix, Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
US20050239700A1
(en)
*
|
2003-10-14 |
2005-10-27 |
Biogen Idec Inc. |
Treatment of cancer using antibodies to LRRC15
|
EP2385069A3
(en)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
WO2005081749A2
(en)
*
|
2004-01-23 |
2005-09-09 |
Avanir Pharmaceuticals, Inc. |
Neutralizing human antibodies to anthraxtoxin
|
US20060246079A1
(en)
|
2003-11-14 |
2006-11-02 |
Morrow Phillip R |
Neutralizing human antibodies to anthrax toxin
|
EP1687029A4
(en)
*
|
2003-11-14 |
2007-05-30 |
Avanir Pharmaceuticals |
NEUTRALIZATION OF HUMAN ANTIBODIES TO ANTHRAX TOXIN GENERATED BY CONCORDANCE TECHNOLOGY
|
WO2005060520A2
(en)
*
|
2003-11-25 |
2005-07-07 |
Dana-Farber Cancer Institute, Inc. |
ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
|
JP2008507257A
(ja)
|
2004-03-19 |
2008-03-13 |
アムゲン・インコーポレーテッド |
V遺伝子の操作を介したヒト抗ヒト抗体の危険性の低減
|
JP4960865B2
(ja)
*
|
2004-06-24 |
2012-06-27 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
脱髄に関連する状態の処置
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
US20060063187A1
(en)
*
|
2004-09-15 |
2006-03-23 |
Hotamisligil Gokhan S |
Modulation of XBP-1 activity for treatment of metabolic disorders
|
WO2006041970A2
(en)
*
|
2004-10-08 |
2006-04-20 |
Abbott Biotechnology Ltd. |
Treatment of respiratory syncytial virus (rsv) infection
|
US20060115485A1
(en)
*
|
2004-10-29 |
2006-06-01 |
Medimmune, Inc. |
Methods of preventing and treating RSV infections and related conditions
|
WO2006074397A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Cripto binding molecules
|
WO2006105021A2
(en)
|
2005-03-25 |
2006-10-05 |
Tolerrx, Inc. |
Gitr binding molecules and uses therefor
|
EP1907001B1
(en)
*
|
2005-06-17 |
2015-07-15 |
Merck Sharp & Dohme Corp. |
Ilt3 binding molecules and uses therefor
|
KR101245462B1
(ko)
|
2005-07-08 |
2013-03-20 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Sp35 항체 및 그의 용도
|
US20100304358A1
(en)
*
|
2005-08-15 |
2010-12-02 |
Shuming Nie |
Methods of identifying biological targets and instrumentation to identify biological targets
|
KR20080080109A
(ko)
|
2005-11-04 |
2008-09-02 |
바이오겐 아이덱 엠에이 인코포레이티드 |
도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
|
CA2627446A1
(en)
*
|
2005-11-21 |
2007-05-31 |
Laboratoires Serono S.A. |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
AU2006320479B2
(en)
|
2005-12-02 |
2012-11-08 |
Biogen Ma Inc. |
Treatment of conditions involving demyelination
|
JP5753339B2
(ja)
*
|
2005-12-09 |
2015-07-22 |
アカデミッシュ メディッシュ セントラム ビーアイジェイ ド ユニバーシテイト バン アムステルダム |
抗体産生細胞の安定性に影響を与える手段および方法
|
EP1974020B1
(en)
*
|
2005-12-16 |
2011-06-15 |
Ribovax Biotechnologies SA |
Methods for obtaining immortalized antibody secreting cells
|
CN101420977B
(zh)
|
2006-01-27 |
2016-08-10 |
比奥根Ma公司 |
Nogo受体拮抗剂
|
MX2008011280A
(es)
*
|
2006-03-06 |
2008-09-12 |
Symphogen As |
Anticuerpor policlonal recombinante para el tratamiento de infecciones por el virus sincitial respiratorio.
|
US20070266448A1
(en)
|
2006-05-11 |
2007-11-15 |
Alexander Lifke |
Method for the production of antibodies
|
US7777008B2
(en)
*
|
2006-06-19 |
2010-08-17 |
Tolerx, Inc. |
ILT3 binding molecules and uses therefor
|
US20080171344A1
(en)
*
|
2006-12-22 |
2008-07-17 |
Kapsner Kenneth P |
Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
|
NZ577976A
(en)
|
2007-01-09 |
2011-12-22 |
Biogen Idec Inc |
Sp35 antibodies and uses thereof
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
RU2009136677A
(ru)
*
|
2007-03-06 |
2011-04-20 |
Симфоген А/С (Dk) |
Рекомбинантные антитела для лечения респираторно-синцитиальных вирусных инфекций
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
AU2008275589B2
(en)
*
|
2007-07-12 |
2013-11-21 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
WO2009042589A1
(en)
*
|
2007-09-24 |
2009-04-02 |
Vanderbilt University |
Monoclonal antibodies to respiratory syncytial virus and uses thereof
|
CA2700197C
(en)
|
2007-11-08 |
2020-09-08 |
Neogenix Oncology, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
CN101952313B
(zh)
*
|
2007-11-27 |
2017-12-15 |
不列颠哥伦比亚大学 |
14‑3‑3η抗体及其用于诊断和治疗关节炎的用途
|
KR100938998B1
(ko)
*
|
2008-01-08 |
2010-01-28 |
(주) 에이프로젠 |
호흡기 신시티움 바이러스에 대한 항체
|
US20090233295A1
(en)
*
|
2008-01-29 |
2009-09-17 |
Elias Georges |
Trim59 directed diagnostics for neoplastic disease
|
LT2285408T
(lt)
|
2008-06-05 |
2019-01-25 |
Ablynx N.V. |
Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
|
US8058406B2
(en)
|
2008-07-09 |
2011-11-15 |
Biogen Idec Ma Inc. |
Composition comprising antibodies to LINGO or fragments thereof
|
EP2145621A1
(en)
|
2008-07-16 |
2010-01-20 |
Stephan Lück |
Prevention of dehydration and reduction of gluconeogenetic losses of amino acids by means of propane-1,2,3-triol
|
JP5575377B2
(ja)
*
|
2008-07-18 |
2014-08-20 |
シスメックス株式会社 |
抗rsウイルスモノクローナル抗体を用いたrsウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗rsウイルスモノクローナル抗体
|
EP2373689A1
(en)
|
2008-12-12 |
2011-10-12 |
MedImmune, LLC |
Crystals and structure of a human igg fc variant with enhanced fcrn binding
|
WO2010078526A1
(en)
|
2008-12-31 |
2010-07-08 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
AU2010228990A1
(en)
|
2009-03-24 |
2011-10-27 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against LIGHT and uses thereof
|
CN102459332B
(zh)
|
2009-06-05 |
2015-08-19 |
埃博灵克斯股份有限公司 |
用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
|
HUE058971T2
(hu)
|
2009-07-15 |
2022-09-28 |
Glaxosmithkline Biologicals Sa |
RSV F fehérjekészítmények és eljárások azok elõállítására
|
WO2011020079A1
(en)
|
2009-08-13 |
2011-02-17 |
Calmune Corporation |
Antibodies against human respiratory syncytial virus (rsv) and methods of use
|
WO2011034582A2
(en)
*
|
2009-09-16 |
2011-03-24 |
Duke University |
Hiv-1 antibodies
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
EP2507262A1
(en)
|
2009-11-30 |
2012-10-10 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
CA2793959C
(en)
|
2010-03-25 |
2019-06-04 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
EP2400298B1
(en)
*
|
2010-05-28 |
2013-08-14 |
F.Hoffmann-La Roche Ag |
Single B-cell cultivation method and specific antibody production
|
BR112012031638B1
(pt)
|
2010-07-09 |
2021-01-12 |
Janssen Vaccines & Prevention B.V. |
anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
|
WO2012006633A1
(en)
|
2010-07-09 |
2012-01-12 |
Biogen Idec Hemophilia Inc. |
Chimeric clotting factors
|
EP2422618A1
(en)
|
2010-08-27 |
2012-02-29 |
Technologie Integrale Ltd. |
Animal model for the evaluation of the efficacy of an HIV vaccine
|
US9956236B2
(en)
|
2011-02-07 |
2018-05-01 |
Cornell University |
Methods for increasing immune responses using agents that directly bind to and activate IRE-1
|
WO2012145572A1
(en)
|
2011-04-20 |
2012-10-26 |
The Trustees Of The University Of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
WO2012170969A2
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
WO2012170765A2
(en)
|
2011-06-10 |
2012-12-13 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
CA2789539A1
(en)
|
2011-09-12 |
2013-03-12 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
EP2756092A4
(en)
*
|
2011-09-16 |
2015-10-28 |
Giovanni Amabile |
METHOD FOR THE PRODUCTION OF CELLS, TISSUE AND ANTIBODIES
|
CN102850454B
(zh)
*
|
2011-09-27 |
2014-06-25 |
上海博沃生物科技有限公司 |
抗呼吸道合胞病毒的人单克隆抗体
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
CA2855746A1
(en)
|
2011-11-16 |
2013-05-23 |
John Stephen HILL |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
TR201809743T4
(tr)
|
2012-01-10 |
2018-07-23 |
Biogen Ma Inc |
Kan beyin bariyerinden terapötik moleküllerin taşınmasının arttırılması.
|
EA030716B1
(ru)
|
2012-05-14 |
2018-09-28 |
Байоджен Ма Инк. |
Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
|
JPWO2014003137A1
(ja)
*
|
2012-06-27 |
2016-06-02 |
旭化成メディカル株式会社 |
高アフィニティー抗体、及びその製造方法
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
WO2014078280A1
(en)
*
|
2012-11-13 |
2014-05-22 |
Genentech, Inc. |
Enrichment of antigen-specific plasmablasts
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
CN104955324A
(zh)
|
2013-01-29 |
2015-09-30 |
巴斯夫植物科学有限公司 |
表达hcp7的抗真菌植物
|
CN104994725B
(zh)
|
2013-01-29 |
2022-07-01 |
巴斯夫植物科学有限公司 |
表达hcp6的抗真菌植物
|
WO2014118018A1
(en)
|
2013-01-29 |
2014-08-07 |
Basf Plant Science Company Gmbh |
Fungal resistant plants expressing ein2
|
TWI659968B
(zh)
|
2013-03-14 |
2019-05-21 |
再生元醫藥公司 |
針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法
|
AR095596A1
(es)
|
2013-03-15 |
2015-10-28 |
Amgen Res (Munich) Gmbh |
Moléculas de unión de cadena única comprendiendo n-terminal abp
|
CA2906960C
(en)
*
|
2013-03-15 |
2021-07-20 |
Xiamen University |
Epitope of rsv fusion protein and antibody recognizing the epitope
|
WO2014140368A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza m2 and cd3
|
TWI788044B
(zh)
|
2013-03-15 |
2022-12-21 |
美商百歐維拉提夫治療公司 |
因子ix多肽調配物
|
US10234456B2
(en)
|
2013-06-21 |
2019-03-19 |
Tanaka Kikinzoku Kogyo K.K. |
Immunochromatography device for detecting RSV
|
EP2848937A1
(en)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Methods of identifying novel HIV-1 immunogens
|
DK3049521T3
(en)
|
2013-09-25 |
2019-04-23 |
Univ Cornell |
Compounds for inducing antitumor immunity and methods thereof
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
JP6317440B2
(ja)
|
2013-10-29 |
2018-04-25 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
酸化ストレスを阻害するための方法および組成物
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
EP3142750B1
(en)
|
2014-05-13 |
2020-07-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising aav expressing dual antibody constructs and uses thereof
|
WO2016016859A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
AR101400A1
(es)
|
2014-07-31 |
2016-12-14 |
Amgen Res (Munich) Gmbh |
Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
|
AU2016205197B2
(en)
|
2015-01-08 |
2021-10-21 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
BR112017016688B1
(pt)
|
2015-02-04 |
2024-01-23 |
Basf Plant Science Company Gmbh |
Método para aumentar a resistência fúngica, método para a produção de um produto e método para criar uma planta resistente a fungos
|
EP3069730A3
(en)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP4276116A3
(en)
|
2015-04-17 |
2024-01-17 |
Amgen Research (Munich) GmbH |
Bispecific antibody constructs for cdh3 and cd3
|
CA2985081A1
(en)
|
2015-05-13 |
2016-12-15 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-influenza antibodies and methods of use thereof
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
CA3011942A1
(en)
|
2016-02-03 |
2017-08-10 |
Amgen Research (Munich) Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
HUE057220T2
(hu)
|
2016-02-03 |
2022-04-28 |
Amgen Res Munich Gmbh |
BCMA és CD3 bispecifikus, T-sejtet kötõ antitest-konstrukciók
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
US10626126B2
(en)
*
|
2016-04-08 |
2020-04-21 |
Pulmocide Limited |
Compounds
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
EP3054014A3
(en)
|
2016-05-10 |
2016-11-23 |
BASF Plant Science Company GmbH |
Use of a fungicide on transgenic plants
|
US11485775B2
(en)
|
2016-10-21 |
2022-11-01 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
US11312761B2
(en)
|
2016-10-21 |
2022-04-26 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
US11479600B2
(en)
|
2016-10-21 |
2022-10-25 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
SG11201907611WA
(en)
|
2017-02-28 |
2019-09-27 |
Univ Pennsylvania |
Influenza vaccines based on aav vectors
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
JP7455579B2
(ja)
|
2017-02-28 |
2024-03-26 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
新規アデノ随伴ウイルス(aav)クレードfベクター及びその用途
|
TW202228779A
(zh)
|
2017-03-01 |
2022-08-01 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
AU2018261951A1
(en)
|
2017-05-05 |
2019-10-31 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
EP3717632B1
(en)
|
2017-11-30 |
2022-10-26 |
F. Hoffmann-La Roche AG |
B-cell cultivation method
|
WO2019118426A1
(en)
|
2017-12-11 |
2019-06-20 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
US20210301017A1
(en)
|
2018-07-30 |
2021-09-30 |
Amgen Research (Munich) Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
BR112021002032A2
(pt)
|
2018-08-03 |
2021-07-20 |
Amgen Research (Munich) Gmbh |
construtos de anticorpos para cldn18.2 e cd3
|
EP3843757B1
(en)
|
2018-08-27 |
2024-04-24 |
Affimed GmbH |
Cryopreserved nk cells preloaded with an antibody construct
|
EP3863670A1
(en)
|
2018-10-11 |
2021-08-18 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
US20220186200A1
(en)
|
2019-03-11 |
2022-06-16 |
Basf Se |
Amylases and methods for making and using them
|
TW202045711A
(zh)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
生物製品製造中基於生物量之自動灌注控制
|
US20220306741A1
(en)
|
2019-09-10 |
2022-09-29 |
Amgen Inc. |
Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
UY38995A
(es)
|
2019-12-20 |
2021-06-30 |
Amgen Inc |
Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
|
CA3160927A1
(en)
|
2019-12-27 |
2021-07-01 |
Affimed Gmbh |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
EP4093771A1
(en)
|
2020-01-22 |
2022-11-30 |
Amgen Research (Munich) GmbH |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
EP4118113A1
(en)
|
2020-03-12 |
2023-01-18 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
|
KR20220155338A
(ko)
|
2020-03-19 |
2022-11-22 |
암젠 인크 |
뮤신 17에 대한 항체 및 이의 용도
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
JP2023527293A
(ja)
|
2020-05-19 |
2023-06-28 |
アムジエン・インコーポレーテツド |
Mageb2結合構築物
|
AU2021281554A1
(en)
|
2020-05-29 |
2022-12-15 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific antibody construct binding to CD33 and CD3
|
IL300314A
(en)
|
2020-10-08 |
2023-04-01 |
Affimed Gmbh |
Coupling materials with triple specificity
|
WO2022096700A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Research (Munich) Gmbh |
Polypeptide constructs selectively binding to cldn6 and cd3
|
AU2021373318A1
(en)
|
2020-11-06 |
2023-05-25 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
UY39508A
(es)
|
2020-11-06 |
2022-05-31 |
Amgen Res Munich Gmbh |
Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
|
IL302597A
(en)
|
2020-11-06 |
2023-07-01 |
Amgen Inc |
Constructive polypeptide binds to CD3
|
CN116670152A
(zh)
|
2020-12-01 |
2023-08-29 |
宾夕法尼亚州大学信托人 |
具有组织特异性靶向基序的新型组合物和含有其的组合物
|
EP4314078A1
(en)
|
2021-04-02 |
2024-02-07 |
Amgen Inc. |
Mageb2 binding constructs
|
KR20240011714A
(ko)
|
2021-04-27 |
2024-01-26 |
제너레이션 바이오 컴퍼니 |
치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도
|
JP2024518369A
(ja)
|
2021-05-06 |
2024-05-01 |
アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング |
増殖性疾患で使用されるcd20及びcd22標的化抗原結合分子
|
CA3216098A1
(en)
|
2021-07-30 |
2023-02-02 |
Uwe Reusch |
Duplexbodies
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
AU2022382368A1
(en)
|
2021-11-03 |
2024-05-02 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|